Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed.
Journal of bacteriology · 2026
Article
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Thaís KlevornDepartment of Microbiology and Immunology, Weill Cornell Medical College, New York, NY, USA.ORCID 0000-0002-2765-1626
Christopher BrownDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA.ORCID 0000-0003-2182-8133
Christine D HardyDepartment of Molecular Biology & Biochemistry, University of California, Irvine, Irvine, CA, USA.ORCID 0000-0002-0780-025X
Bonnie J CuthbertDepartment of Molecular Biology & Biochemistry, University of California, Irvine, Irvine, CA, USA.ORCID 0000-0001-5176-8245
Amanda SpencerDepartment of Chemistry & Biochemistry, Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California, San Diego, San Diego, CA, USA.ORCID 0009-0004-0270-1545
Adrián JinichDepartment of Chemistry & Biochemistry, Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California, San Diego, San Diego, CA, USA.ORCID 0000-0001-8616-9250
Luming ChanDepartment of Microbiology and Immunology, Weill Cornell Medical College, New York, NY, USA.
Shiva K AngalaMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.
Jordan ManzerMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.
Jessica MendozaDepartment of Molecular Biology & Biochemistry, University of California, Irvine, Irvine, CA, USA.
Rodger de MirandaDepartment of Molecular Biology & Biochemistry, University of California, Irvine, Irvine, CA, USA.
Heather KimDepartment of Microbiology and Immunology, Weill Cornell Medical College, New York, NY, USA.ORCID 0000-0003-3152-5785
Dirk SchnappingerDepartment of Microbiology and Immunology, Weill Cornell Medical College, New York, NY, USA.ORCID 0000-0002-4445-7219
Mary JacksonMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.ORCID 0000-0002-9212-0258
Kyu RheeImmunology and Microbial Pathogenesis Graduate Program, Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY, USA.ORCID 0000-0003-4582-2895
Celia W GouldingDepartment of Molecular Biology & Biochemistry, University of California, Irvine, Irvine, CA, USA.ORCID 0000-0001-5582-0565
Sabine EhrtDepartment of Microbiology and Immunology, Weill Cornell Medical College, New York, NY, USA.ORCID 0000-0002-7951-2310
Funding
UC San Diego FIRST ProgramU54CA272220 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Deborah L Wingard · 2022 to 2026
$21.2M
Vulnerabilities in Mycobacterial Cell-Wall BiogenesisP01AI095208 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI SASSETTI, CHRISTOPHER M · 2012 to 2022
$19.8M
Assembly and export of mycobacterial lipoglycansR01AI155674 · NIAID · COLORADO STATE UNIVERSITY · PI JACKSON, MARY · 2021 to 2025
$3.0M
T32 for Training in Microbiology & Infectious DiseasesT32AI141346 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI Celia Goulding, Melissa Bruckner Lodoen · 2019 to 2026
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A periplasmic protein complex mediates arabinofuranosyltransferase activity and intrinsic drug resistance in · full record | OpenQuestion